Q-omics provides the consensus-scored CCDC170 profile across patient tissues and cancer cell-line models. CCDC170 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCDC170 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, CCDC170 RNA expression shows 21,249 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, THCA, and BRCA as cancer lineages where CCDC170 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC170 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC170 survival associations across molecular data types. CCDC170 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC170 RNA expression–survival associations across cancer types. High CCDC170 expression shows unfavorable associations in ACC and LAML, but favorable associations in HNSC, SKCM, BRCA and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CCDC170 RNA expression.
This table summarizes CCDC170 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC170. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC170 shows lower tumor expression in THCA, KICH, LUAD and LUSC and higher tumor expression in LIHC and COAD. The THCA box plot shows higher CCDC170 RNA expression in normal versus tumor tissue (log2 FC = −1.587, t-test p < 0.001).
This table shows molecular features associated with CCDC170 in patient tissues and cancer cell lines. In patient samples, CCDC170 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC170 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BREAST.
